Back to Ovarian Cancer
NCT01521325
NCT01521325
Who may be able to join
Who might be able to join this trial:
- You are 18 years of age or older (male or female)
- You have been diagnosed with a cancer that has been confirmed by lab testing to express a protein called mesothellin
- Your cancer can be measured or tracked, has gotten worse despite previous treatment, and includes at least one tumor outside the liver that is large enough to be seen on imaging (at least 1.5 cm), or your disease can be evaluated through symptoms, blood markers, scans, or tissue samples done within the past 4 weeks
Who may not be able to join:
- You have a known allergy or bad reaction to a type of medication called monoclonal antibodies
- Your body has been known to develop a specific immune reaction called HACA (confirm with trial site)
- You have previously been treated with a drug called amatuximab
- You have previously been treated with a drug called SS1(dsFv)PE38 (also known as SS1P)
- You have taken part in another experimental treatment within the past 30 days
- You have cancer that has spread to the brain
- You have an implanted device (such as certain metal implants) that would interfere with imaging scans of your tumors
- You have received chemotherapy, biological therapy, radiation therapy, or immunotherapy within the past 3 weeks before starting this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 1
Sponsor
Morphotek
Registry
clinicaltrials_gov
Start date
1 September 2011
Est. completion
1 March 2013
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Primary Objective: determine biodistribution of radiolabeled amatuximab in tumor and nontumor tissue
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.